Endoplasmic reticulum-targeting activatable nanophotosensitizers for hypoxia relief and enhanced photodynamic therapy

Abstract

Photodynamic therapy (PDT) is a promising cancer therapeutic modality. However, the specific targeting capability of conventional photosensitizers is relatively low, which significantly suppresses the efficacy of PDT. In this study, an endoplasmic reticulum (ER)-targeting nanophotosensitizer (TPPa-Y NP) was designed and prepared for enhanced PDT. TPPa-Y NP is prepared by encapsulating an ER-targeting pheophorbide-a (TPPa) and a hypoxia inducible factor 1α (HIF-1α) inhibitor (YC-1) with a hydrogen peroxide (H2O2) responsive amphiphilic copolymer (PEG-PMPAP). After being internalized into tumor cells, TPPa-Y NPs may rapidly dissociate and release both TPPa and YC-1. TPPa can target ER, which leads to the enhance of its fluorescence signal and PDT efficacy. On the other hand, YC-1 may effectively inhibit the overexpressed HIF-1α and alleviate tumor hypoxia, which can further enhance the PDT efficacy of TPPa. Both in vitro and in vivo studies demonstrate that TPPa-Y NPs have better anticancer effect than the nanoparticles without YC-1 (TPPa NPs). Therefore, this study provides a smart nanophotosensitizer which is able to target ER and alleviate hypoxia for PDT efficacy enhancement.